15 N]glutamine in patients with gastrointestinal cancer we unexpectedly observed a gradual decrease in time of the appearance rate (R a ) of glutamine in plasma. Here we investigate whether the failure to achieve a plateau isotopic enrichment in plasma is, among other factors, due to incomplete equilibration of the glutamine tracer with the large intramuscular free glutamine pool.
INTRODUCTION
Glutamine is the most abundant free amino acid in the human body and can be synthesized from glutamate and ammonia by the enzyme glutamine synthetase in various tissues. Muscle tissue is a major site for glutamine synthesis in the human body [1] [2] [3] and contains over 90 % of the large whole-body glutamine pool [4, 5] . Glutamine has several pivotal biochemical properties which suggest it plays an important role in health and disease. Among these are the transport of nitrogen from the periphery to visceral organs, the maintenance of acid\base balance, the provision of fuel for rapidly dividing cells and of nitrogen for de novo synthesis of nucleotides [6] .
The rationale for clinical dietary regimens to include glutamine stems from the hypothesis that severely or chronically ill patients, who often have a reduced muscle mass, produce insufficient amounts of glutamine to meet their increased needs [7] . However, actual data on glutamine production and utilization in vivo in humans are scarce and are limited primarily to studies in healthy individuals. Most of the current knowledge of glutamine metabolism has been gained from invasive studies using determination of arteriovenous concentration differences across different organ beds and from whole-body flux measurements with stable isotope tracers. To judge whether endogenous glutamine production was depressed in patients with gastrointestinal malignancies, we measured whole-body glutamine fluxes by the traditional approach. In contrast to previous studies in healthy subjects we did not observe a steady state in plasma glutamine enrichment between 2 and 6 h of infusion with L-[5-"&N]glutamine. Instead, glutamine enrichment in plasma gradually increased for the duration of the study.
Therefore, the aim of the present study was to investigate the mechanism behind this ongoing rise in plasma enrichment. We specifically investigated the potential role and relative contribution of (1) incomplete equilibration of the glutamine tracer with the large muscle compartment, (2) recycling of the labelled amide nitrogen, and (3) gradual changes in the contribution of protein breakdown to glutamine production. Patients were infused with L-[5-"&N]glutamine for periods of up to 11 h. Arterial blood samples and percutaneous muscle biopsies were taken and analysed for glutamine enrichment to determine to what extent and at what rate the intravenously administered glutamine tracer mixes with the large glutamine pool in skeletal muscle. To investigate recycling of the amide-"&N of glutamine a simultaneous infusion of L-[1-"$C]glutamine was given to a subgroup of patients. Two essential amino acid tracers, L-[1-
]phenylalanine, were used to determine the contribution of protein degradation to glutamine production throughout the study.
METHODS

Patients
Twenty patients (12 males and 8 females, aged 62p13 years) admitted to the hospital for elective abdominal surgery participated in the study. The patients had a normal body mass index (23.4p0.7 kg\m#) and most had a stable body weight. Underlying diseases were colorectal cancer (n l 8), gastric cancer (n l 4), intra-abdominal carcinoid (n l 1), villous adenoma (n l 2), gastric volvulus (n l 1), diverticular disease (n l 1), ulcerative colitis (n l 1) and Crohn's disease (n l 2). No clinical signs of inflammatory activity were present. Written informed consent was obtained from all patients under the protocol as approved by the Medical Ethics Committee of the University Hospital Maastricht. 
Materials
L-[5-"&N]Glutamine (99 % "&N in the amide nitrogen), L-[1-"$C]glutamine (99 % "$C), L-[1-"$C]leucine (99 % "$C)
Study design
The measurements were performed 1 or 2 days before surgery. Patients were fasted overnight and remained fasted until the study was complete. On the morning of the study two catheters were inserted : one into an antecubital vein for isotope infusion and the other into the radial artery for blood sampling. The arterial catheter was kept patent by a slow 0.9 % NaCl infusion. ]-phenylalanine (priming dose 3.64 µmol\kg ; infusion rate 3.64 µmol:h −" :kg −" ). Blood samples were drawn in chilled-on-ice heparinized tubes before the start of the tracer infusion for measurement of baseline enrichment and then at 0.5-2-h intervals throughout the study. Plasma was obtained by centrifugation of whole blood at 3500 r.p.m. (2200 g) at 4 mC for 5 min. For the determination of glutamine concentration plasma was deproteinized with sulphosalicylic acid [8] , vortexed, frozen in liquid nitrogen and stored at k80 mC. For tracer enrich-ment measurements plasma was frozen and stored at k80 mC until analysis. Percutaneous muscle biopsies were taken from the anterior tibial muscle at one to three time points during the tracer infusion to measure glutamine enrichment and concentration in the intracellular free glutamine pool in muscle. Biopsies were taken using the conchotome technique as described previously [9] . Blood, visible fat and connective tissue were quickly removed from the specimen, and the tissue was immediately frozen in liquid nitrogen and subsequently stored at k80 mC for later analysis. To limit the number of biopsies in each patient, baseline enrichment in muscle was assumed to equal that in plasma.
Analytical procedures
The biopsies were freeze-dried and further freed from adherent blood and connective tissues. The water content of the biopsies was calculated from the weight difference before and after freeze-drying and used for conversion from wet to dry weight. The muscle specimens were powdered and deproteinized using a Mini-Beadbeater (Biospeck Products, Bartlesville, U.S.A.). Approximately 30 mg of the pulverized tissue was added to 350 µl of 5% sulphosalicylic acid and 0.1-g glass beads (diameter 1 mm, Biospeck Products) and beaten for 30 s. The supernatant was frozen in liquid nitrogen and stored at k80 mC until later analysis. The concentration of glutamine in supernatant, plasma and tracer infusate was determined by fully automated HPLC [10] .
The "&N and "$C enrichment of plasma and muscle glutamine was determined using GC combustion isotope ratio MS (Finnigan MAT 252, Bremen, Germany). In brief, deproteinized plasma and muscle extracts were passed over an ion-exchange column and the eluted amino acids were freeze-dried and then derivatized with N-methyl -N-(tert -butyldimethylsilyl )-trifluoroacetamide (MTBSTFA) (Pierce Europe, The Netherlands) into the tert-butyldimethylsilyl (TBDMS) derivative as described previously [11] . The resulting molecule (C
contains three TBDMS groups attached to the carboxy, the 2-amino and the 5-amide group of glutamine respectively. After injection and baseline separation in the gas chromatograph the amino acid derivative is combusted in the capillary-sized combustion interface and the pulses of N # and CO # generated are introduced on-line into the IRMS in a stream of helium. The enrichment of glutamine standards was linear from natural abundance up to j1.0 APE (atom percentage excess) both for "$C and "&N. The reproducibility of seven repeated measurements was p0.0002 APE or better for carbon and p0.001 APE or better for nitrogen over the specified enrichment range both for standards and biological samples. The precision of the measurements was checked with standards by comparing enrichments obtained after straight elemental analyser combustion (Carlo Erba-MAT 252 combination, Bremen, Germany) and measurement of the same standards as TBDMS derivatives and found to be of the same magnitude as the reproducibility over the entire abundance range. Plasma [1-"$C]α-ketoisocaproate (KIC) enrichment was measured using a quinoxalinoltrimethylsilyl derivative and a GC-MS system (Finnigan Incos XL, San Jose, CA, U.S.A.) as previously described [12] . Plasma phenylalanine was derivatized to its TBDMS derivative and its deuterium enrichment was determined by GC-MS (Finnigan Incos XL), in a similar manner to that described previously [13] . Final values for phenylalanine and KIC determinations were corrected using calibration curves. The within-assay coefficient of variation for enrichment determinations was less than 3 % for both 
Calculations
The appearance rate of glutamine, phenylalanine and leucine into plasma was calculated by the standard isotope expression for dilution of the infused tracer amino acid in plasma : R a l i(E i \E p k1), where R a is the rate of amino acid appearance (µmol:h −" :kg −" ), E i and E p are the amino acid tracer enrichments (in MPE) in the infusate and in plasma respectively, and i is the tracer infusion rate (µmol:h −" :kg −" ). This expression is based on a single pool model and describes the appearance rate of the amino acid into the sampled compartment. In a single pool model it is assumed that the R a of tracee and the infusion of tracer is into, and sampling is from, a single, homogenous, instantly mixing pool.
We have assumed that amino acids are released from proteolysis in proportion to their relative content in muscle protein. Rates of protein catabolism were calculated by assuming the phenylalanine and leucine content in protein are 4.3 g and 8.0 g\100 g protein respectively, based on averages of amino acid composition of mammalian tissues as previously described [14] . The R a of phenylalanine was calculated from arterial [#H & ]phenylalanine enrichments, which were corrected to mixed venous values as described before [15] . The glutamine appearance from protein breakdown was calculated by using the average of the appearance rates of leucine and phenylalanine. It was assumed that glutamine residues contributed to half of the total glutamine and glutamate content of 13.9 g\100 g protein, i.e. 6.95 g\100 g protein [16] .
Statistics
Data are given as meanspS.E.M. Comparisons between different time points were made using the Wilcoxon matched pairs signed rank sum test. For comparison of "&N and "$C enrichment data linear regression analysis was applied to quantify the slope and intercept of the enrichment curves. A P value of 0.05 was considered statistically significant.
RESULTS
The arterial "&N enrichment of glutamine increased for the duration of the study (Figure 1 (Figure 2 , P 0.001), indicating that mixing occurred of the glutamine tracer with the intracellular free glutamine pool in skeletal muscle. In each patient the intramuscular enrichment was lower than the arterial enrichment, but relative rises in glutamine enrichment were consistently larger for muscle than for plasma. Consequently, the ratio between intramuscular and arterial enrichment significantly increased during tracer infusion : average values were 0.076p0.006 at 2 h (n l 10), 0.106p0.016 at 4 h (n l 4), 0.157p0.011 at 6 h (n l 20), and 0.263p0.022 at 11 h (n l 5).
Inspection of the rise in enrichment with time of both plasma and intramuscular free glutamine indicated that isotopic steady state was not achieved after 11 h infusion in any patient. The whole-body pool in which the glutamine tracer equilibrated was not a single, instantly mixing compartment, and therefore conditions for application of the R a l i(E i \E p k1) equation were not fulfilled. However, if, for the sake of comparison with Enrichments were averaged at each time point for the five subjects studied during 11 h (upper line) and for the 15 subjects studied during 6 h (lower line). previous data in the literature, we used the isotopic data to calculate the appearance rate of glutamine into plasma, the values obtained would have been lower by the end of the tracer infusion than shortly after the onset of infusion (Table 1) . When [1-"$C]glutamine was simultaneously infused with [5-"&N]glutamine the rate of rise in enrichment observed for [1-"$C]glutamine in both plasma and muscle was lower than that observed for the "&N-labelled amino acid (Figure 3 ). Linear regression revealed that the "&N enrichment of glutamine in plasma increased by 0.012p0.002 MPE\h, whereas the "$C enrichment rose by 0.008p0.002 MPE\h (n l 5, P 0.05). Increments similar to those in plasma were observed for the enrichment of glutamine in muscle : 0.011p0.002 and 0.008p0.001 MPE\h for "&N and "$C respectively (P 0.05). When the rate of rise in each patient was divided by the tracer enrichment, values were obtained of 0.040p0.007 per hour for plasma glutamine "&N and 0.028p0.006 per hour (P 0.05) for glutamine "$C.
Extrapolating the enrichment data in plasma to time 0 yielded glutamine R a values that were not different for the "$C and "&N labels :
261p16 and 249p17 µmol:h −" :kg −" respectively. By the end of the 11-h tracer infusion period, glutamine R a averaged 205p18 µmol:h −" :kg −" for the "$C tracer compared with 185p14 µmol:h −" :kg −" for the "&N tracer ( Enrichments were averaged at each time point for the five subjects studied during 11 h. >, plasma glutamine 15 N enrichments ; =, plasma glutamine 13 C enrichments ; , intramuscular glutamine 15 N enrichments ; , intramuscular glutamine 13 C enrichments. The values of muscle glutamine enrichment were not corrected for the water distribution between the intracellular and extracellular spaces. Figure 4 . In the 6-h experiments protein breakdown calculated with the phenylalanine tracer averaged 179p16 and 163p13 mg protein:h −" :kg −" at t l 2 and t l 6 h respectively (P 0.05). When the leucine tracer was used, proteolysis amounted to 184p8 mg protein: kg −" :h −" at t l 2 h and 174p6 mg protein:kg −" :h −" at Enrichments were averaged at each time point for the five subjects studied during 11 h (upper line) and for the 15 subjects studied during 6 h (lower line) t l 6 h (P 0.05). In the 11-h studies, proteolysis was 161p11 (t l 2 h) and 153p5 (t l 11 h) mg protein:h −" : kg −" for the phenylalanine tracer, and 169p14 (t l 2 h) and 142p6 (tl11 h) mg protein:h −" :kg −" for the leucine tracer, (P 0.05). The corresponding estimates of glutamine release from proteolysis are shown in Table 1 . Calculation revealed that the reduction in glutamine release directly from protein breakdown accounted for 16p6 % (11-h study) and 21p4 % (6-h study) of the decline observed in overall glutamine R a . Plasma glutamine concentration averaged 606p19 µmol\l. The concentration of glutamine in the intracellular free glutamine pool in muscle was 12.8p0.6 mmol\l intracellular water (assuming that 15 % of the total tissue water is extracellular water [4] ). In four patients, arterial glutamine concentrations were measured throughout the course of their 6-h study. No significant change in glutamine concentration was observed. Average values were 587p64 µmol\l before onset of the tracer infusion and 615p55 µmol\l at 6 h. Muscle free glutamine concentration did not change either during the course of the study : 12.1p0.8 (t l 2 h) versus 11.2p0.6 (t l 6 h) mmol\l intracellular water in the 6-h study, and 14.4p1.6 (t l 4 h), 12.7p0.9 (t l 6 h) and 12.9p1.3 (t l 11 h) mmol\l intracellular water in the 11-h study.
DISCUSSION
In this study we unequivocally showed that isotopic steady-state conditions were not achieved in patients with gastrointestinal disease during an 11-h primed constant intravenous infusion of glutamine tracers. Therefore, the relative contribution of some processes that might have contributed to the ongoing rise in plasma glutamine "&N enrichment was investigated.
To establish whether recycling of labelled nitrogen contributed to the rise in plasma glutamine "&N enrichment, a comparison was made with the enrichment curve of simultaneously infused [1-"$C]glutamine. Recycling of the labelled C1-carbon between the glutamate and glutamine pool is probably negligible because oxidation is the predominant fate of an infused [1-"$C]glutamate tracer [17] . Recycling via the Krebs cycle does not occur because the labelled C1-carbon is released as "$CO # in the conversion of α-ketoglutarate to succinate. Insignificant differences, in line with minimal C1-carbon cycling, were also observed by other researchers between plasma glutamine R a measured using either a [1-"$C]-and [3,4-$H]glutamine tracer [16] , or a [U-"%C]-and [3,4-$H]glutamine tracer [18] . Recycling of the amide nitrogen label used in the present study could have occurred through reincorporation of "&N ammonia released by glutaminase action back into glutamine via glutamine synthetase. Recycling of the nitrogen label into the amino nitrogen of glutamine is probably minimal, since insignificant enrichment in either plasma glutamine or glutamate amino nitrogen has been observed by us (results not shown) and by others [5] during infusion of [5-"&N] glutamine. Comparison of the increase in plasma glutamine "&N and "$C enrichment observed in the period from 2 to 11 h of tracer infusion revealed that recycling of the nitrogen label could explain only a minor part (15p5 %) of the observed rise in plasma glutamine "&N enrichment (Table 1) .
A small increase occurred in the plasma enrichment of leucine and phenylalanine during the course of the study. As a result the rate of whole-body protein breakdown calculated from these enrichment data slightly decreased throughout the study, as did the release of glutamine from proteolysis (Table 1) . By comparing the reduction in glutamine from proteolysis with the observed decrease in whole-body glutamine R a , we estimated that 16-21 % of the decline in overall R a could be attributed to a reduction in the release of glutamine from proteolysis. The decline in the contribution of protein breakdown to glutamine production and recycling of the "&N label together contributed approximately 30-35 % to the decrease in glutamine R a .
An important reason for the observed lack of isotopic steady state appeared to be incomplete equilibration of the glutamine tracer with a large second pool. Skeletal muscle is a major contributor to this second pool, but other tissues and cells may also be part of it. For instance, equilibration of glutamine between erythrocytes and plasma was found to be far from complete after 4 h of glutamine tracer administration [5] . Direct measurement of the glutamine enrichment in muscle clearly demonstrated that glutamine tracers do enter the large intracellular free glutamine pool in muscle, but the increase in enrichment is slow. The linearity observed in the rise in intramuscular enrichment indicated that near-isotopic steady state was not even approached by 11 h of glutamine tracer infusion. The slow equilibration with the muscle pool is probably due to the enormous size of the intramuscular free glutamine pool and the speed of entry of glutamine into muscle. From the expected size of the muscle free glutamine pool and the reported kinetics of glutamine transport in human skeletal muscle [19] it can be deduced that the process of isotope equilibration with the muscle pool will take many hours. Compartmentalization of glutamine within cells, as suggested by the limited erythrocyte glutamine exchange [5] and the slow mixing of plasma and intramuscular glutamine demonstrated here, may further slow down the process of equilibration. It is impossible to quantify exactly the contribution of incomplete equilibration to the decrease in glutamine R a as other unquantified factors (such as changes in glutamine synthesis rate) may also be important. However, our finding that the muscle glutamine pool equilibrates so slowly interferes with the interpretation of glutamine kinetics measured by the tracer dilution method, i.e. the measured R a of glutamine into plasma does not reflect the whole-body flux but rather reflects transport rates through plasma [5] . Similar considerations may apply to the flux measurements of other amino acids with large muscle pools such as alanine and glutamate.
A relevant question is why the gradual increase in plasma glutamine enrichment that we see in this patient population may have remained unnoticed by previous researchers. First, steady-state conditions for the tracer infused have usually been determined on the basis of a quick succession of plasma enrichment measurements within a sampling period of 2 h or less [14, 16, 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . This period may have been too short to assess the fractional change in glutamine enrichment shown here over a period of 6-11 h : 0.028 and 0.040 per hour for the "$C and "&N tracer respectively. Second, the traditional GC-MS methods which have been used previously for measuring plasma and muscle glutamine enrichments [5, 14, 16, 18, [20] [21] [22] [23] [24] [25] [26] [27] may not have the required precision to accurately measure low enrichments such as in muscle or to detect small systematic increases in plasma enrichment. The combination of very precise GC combustion isotope ratio MS measurement with prolonged tracer infusion periods has enabled us to conclude that steady-state conditions of the glutamine tracer were not achieved.
Although the subjects included in this study had gastrointestinal disease and in general were older than those in other studies, the plasma glutamine R a measured after 2 h of [5-"&N]glutamine infusion was in the range previously observed in young healthy volunteers : mean R a of 276 compared with 270-305 µmol:h −" :kg −" [5, 24, 30] . Darmaun et al. [26] previously showed a 20 % reduction in the glutamine R a in lean but weight-stable patients with a short bowel, whereas an increased glutamine R a has been observed in weight-losing patients with malnutrition due to non-neoplastic gastrointestinal disease, including short bowel patients [27] . The majority of our patients were well-nourished and had a stable body weight. Their intramuscular glutamine concentration was slightly below normal (12.8 versus 14-20 mmol\l intracellular water) [4, 30, 31] , which could be due to either different muscle types (tibialis anterior versus quadriceps femoris) or disease. It is widely recognized that a decline of intramuscular glutamine occurs in a wide variety of conditions of disease and injury [32] . Although we do not know how widely applicable the present finding of incomplete equilibration of the glutamine tracer is, it is not likely to be specific for the patient population involved, because little mixing of plasma and intramuscular glutamine has also been suggested in healthy subjects [5] . Therefore, care should be taken in the interpretation of plasma glutamine R a as it may not reflect the whole-body glutamine flux.
In conclusion, continued net uptake of the glutamine tracer in skeletal muscle contributes to the absence of isotopic steady state in patients with gastrointestinal disease. As a consequence, calculation of the plasma glutamine R a during a short tracer infusion, when intracellular muscle has little enrichment, overestimates the whole-body glutamine flux. We continue our attempts to estimate the whole-body production rate of glutamine with a tracer dilution method, as this is the physiological variable desired to judge whether patients with a variety of diseases are in need of glutamine supplementation.
